WO2002051429A3 - Verwendung einer zusammensetzung zur stimulation des nervenwachstums, zur inhibition der narbengewebsbildung, zur reduktion eines sekundärschadens und/oder zur akkumulation von makrophagen - Google Patents

Verwendung einer zusammensetzung zur stimulation des nervenwachstums, zur inhibition der narbengewebsbildung, zur reduktion eines sekundärschadens und/oder zur akkumulation von makrophagen Download PDF

Info

Publication number
WO2002051429A3
WO2002051429A3 PCT/EP2001/015147 EP0115147W WO02051429A3 WO 2002051429 A3 WO2002051429 A3 WO 2002051429A3 EP 0115147 W EP0115147 W EP 0115147W WO 02051429 A3 WO02051429 A3 WO 02051429A3
Authority
WO
WIPO (PCT)
Prior art keywords
macrophages
composition
accumulation
inhibition
reduction
Prior art date
Application number
PCT/EP2001/015147
Other languages
English (en)
French (fr)
Other versions
WO2002051429A2 (de
Inventor
Philippe P Monnier
Bernhard K Mueller
Jan Schwab
Original Assignee
Migragen Ag
Philippe P Monnier
Bernhard K Mueller
Jan Schwab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Migragen Ag, Philippe P Monnier, Bernhard K Mueller, Jan Schwab filed Critical Migragen Ag
Priority to JP2002552571A priority Critical patent/JP2004519448A/ja
Priority to AU2002217149A priority patent/AU2002217149A1/en
Priority to US10/451,487 priority patent/US20040151739A1/en
Priority to EP01272037A priority patent/EP1345619A2/de
Publication of WO2002051429A2 publication Critical patent/WO2002051429A2/de
Publication of WO2002051429A3 publication Critical patent/WO2002051429A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Die vorliegende Erfindung betrifft die Verwendung einer Zusammensetzung enthaltend ein Fusionsprotein und mindestens einen Transporter zur In-vivo-Inhibition der Narbengewebsbildung, zur In-vivo-Reduktion eines Sekundärschadens und/oder zur In-vivo-Akkumulation von Makrophagen, Wobei das Fusionsprotein mindestens eine Bindungsdomäne für den Transporter und mindestens eine Moldulationsdomäne zur kovalenten Modifikation von kleinen GTP-bindenden Proteinen enthält, und der Transporter die Aufnahme des Fusionsproteins in eine Zielzelle vermittelt.
PCT/EP2001/015147 2000-12-22 2001-12-20 Verwendung einer zusammensetzung zur stimulation des nervenwachstums, zur inhibition der narbengewebsbildung, zur reduktion eines sekundärschadens und/oder zur akkumulation von makrophagen WO2002051429A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2002552571A JP2004519448A (ja) 2000-12-22 2001-12-20 神経成長の刺激、瘢痕組織形成の抑制、二次損傷の低減及び／又はマクロファージ蓄積のための組成物の使用
AU2002217149A AU2002217149A1 (en) 2000-12-22 2001-12-20 Use of a composition for the stimulation of nerve growth, the inhibition of scar tissue formation, the reduction of secondary damage and/or the accumulation of macrophages
US10/451,487 US20040151739A1 (en) 2000-12-22 2001-12-20 Use of a composition for the stimulation of nerve growth, the inhibition of scar tissue formation, the reduction of secondary damage and/or the accumulation of macrophages
EP01272037A EP1345619A2 (de) 2000-12-22 2001-12-20 Verwendung einer zusammensetzung zur stimulation des nervenwachstums, zur inhibition der narbengewebsbildung, zur reduktion eines sekundärschadens und/oder zur akkumulation von makrophagen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10064195A DE10064195A1 (de) 2000-12-22 2000-12-22 Verwendung einer Zusammensetzung zur Stimulation des Nervenwachstums, zur Inhibition der Narbengewebsbildung und/oder Reduktion eines Sekundärschadens
DE10064195.4 2000-12-22

Publications (2)

Publication Number Publication Date
WO2002051429A2 WO2002051429A2 (de) 2002-07-04
WO2002051429A3 true WO2002051429A3 (de) 2003-06-19

Family

ID=7668395

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/015147 WO2002051429A2 (de) 2000-12-22 2001-12-20 Verwendung einer zusammensetzung zur stimulation des nervenwachstums, zur inhibition der narbengewebsbildung, zur reduktion eines sekundärschadens und/oder zur akkumulation von makrophagen

Country Status (6)

Country Link
US (1) US20040151739A1 (de)
EP (1) EP1345619A2 (de)
JP (1) JP2004519448A (de)
AU (1) AU2002217149A1 (de)
DE (1) DE10064195A1 (de)
WO (1) WO2002051429A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858298B1 (en) * 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
CA2367636C (en) 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
US20060134140A1 (en) * 2001-04-12 2006-06-22 Dana Lasko Compositions and methods for treating tumor spreading
JP2007070225A (ja) * 2003-07-25 2007-03-22 Yukako Fujinaga クロストリジウム属菌由来成分を含む医薬製剤
US20080160552A1 (en) * 2006-12-13 2008-07-03 Dolly Mehta Methods and Compounds for Treating Inflammation
KR20130056348A (ko) * 2008-09-25 2013-05-29 인비보 테라퓨틱스 코포레이션 척수 외상, 염증, 및 면역 질환: 치료제의 국소적 제어 방출

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008533A1 (en) * 1997-08-13 1999-02-25 Yale University Central nervous system axon regeneration
DE19735105A1 (de) * 1997-08-13 1999-03-04 Univ Albert Ludwigs Freiburg Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008533A1 (en) * 1997-08-13 1999-02-25 Yale University Central nervous system axon regeneration
DE19735105A1 (de) * 1997-08-13 1999-03-04 Univ Albert Ludwigs Freiburg Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
H. BARTH ET AL: "The N-Terminal Part of the Enzyme Component (C2I) of the Binary Clostridium botulinum C2 Toxin Interacts with the Binding Component C2II and Functions as a Carrier System for a Rho ADP-Ribosylating C3-Like Fusion Toxin", INFECTION AND IMMUNITY, vol. 66, no. 4, April 1998 (1998-04-01), pages 1364 - 1369, XP002233432 *
M. LEHMANN ET AL: "Inactivation of Rho Signaling Pathway Promotes CNS Axon Regeneration", THE JOURNAL OF NEUROSCIENCE, vol. 19, no. 17, 1 September 1999 (1999-09-01), pages 7537 - 7547, XP002233431 *
M. LERM ET AL: "Bacterial protein toxins targeting Rho GTPases", FEMS MICROBIOLOGY LETTERS, vol. 188, 2000, pages 1 - 6, XP002233433 *
SANDVIG K ET AL: "Entry of ricin and Shiga toxin into cells: molecular mechanisms and medical perspectives", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 19, no. 22, 15 November 2000 (2000-11-15), pages 5943 - 5950, XP002228667, ISSN: 0261-4189 *

Also Published As

Publication number Publication date
US20040151739A1 (en) 2004-08-05
JP2004519448A (ja) 2004-07-02
DE10064195A1 (de) 2002-07-11
AU2002217149A1 (en) 2002-07-08
EP1345619A2 (de) 2003-09-24
WO2002051429A2 (de) 2002-07-04

Similar Documents

Publication Publication Date Title
AU1194601A (en) Implantable prosthetic valve
AU9314598A (en) Daisy-chainable sensors and stimulators for implantation in living tissue
AU2001289098A1 (en) Implantable prosthesis
AU5311500A (en) Implantable joint prosthesis
WO2003015612A3 (en) Materials and methods to promote repair of nerve tissue
IL207008A (en) Tissues that have undergone cellular or synthetic tissue containing human placental stem cells and methods for their preparation
AU1068800A (en) Prosthetic heart valve
AU8116601A (en) Implantable joint prosthesis
AU6329598A (en) Stabilization sling for use in minimally invasive pelvic surgery
AU1236701A (en) Applicator for laparoscopic or endoscopic surgery
AU2001233227A1 (en) Artificial heart valve
AU3863199A (en) Two piece prosthetic heart valve
AU6515499A (en) Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
WO2003099375A3 (en) Adjustable implantable captivation fixation anchor-stop
AU2002212764A1 (en) Body prosthetic implement
AU6275299A (en) Minimally invasive cardiac surgery procedure
AU1221201A (en) Antisense modulation of y-box binding protein 1 expression
AU4545600A (en) Surgical, grooved director for collecting tissue in a minimally invasive manner
AU2001278338A1 (en) Methods and compositions for modulating tumor growth
AU2003254677A1 (en) Innervated artificial tissues and uses thereof
WO2002051429A3 (de) Verwendung einer zusammensetzung zur stimulation des nervenwachstums, zur inhibition der narbengewebsbildung, zur reduktion eines sekundärschadens und/oder zur akkumulation von makrophagen
EP1223953A4 (de) Fusions-polypeptide zur gewebegeneration und wundheilung zur gezielten matrixanwendung
AU1878201A (en) Composition for the treatment of damaged tissue
AU9487698A (en) Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy
WO2000078803A3 (en) Use of eif4e binding agents in therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002552571

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001272037

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001272037

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10451487

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2001272037

Country of ref document: EP